» Articles » PMID: 37497672

Global, Regional, and National Economic Consequences of Stroke

Abstract

Background: An understanding of global, regional, and national macroeconomic losses caused by stroke is important for allocation of clinical and research resources. The authors investigated the macroeconomic consequences of stroke disease burden in the year 2019 in 173 countries.

Methods: Disability-adjusted life year data for overall stroke and its subtypes (ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage) were collected from the GBD study (Global Burden of Disease) 2019 database. Gross domestic product (GDP, adjusted for purchasing power parity [PPP]) data were collected from the World Bank; GDP and disability-adjusted life year data were combined to estimate macroeconomic losses using a value of lost welfare (VLW) approach. All results are presented in 2017 international US dollars adjusted for PPP.

Results: Globally, in 2019, VLW due to stroke was $2059.67 billion or 1.66% of the global GDP. Global VLW/GDP for stroke subtypes was 0.78% (VLW=$964.51 billion) for ischemic stroke, 0.71% (VLW=$882.81 billion) for intracerebral hemorrhage, and 0.17% (VLW=$212.36 billion) for subarachnoid hemorrhage. The Central European, Eastern European, and Central Asian GBD super-region reported the highest VLW/GDP for stroke overall (3.01%), ischemic stroke (1.86%), and for subarachnoid hemorrhage (0.26%). The Southeast Asian, East Asian, and Oceanian GBD super-region reported the highest VLW/GDP for intracerebral hemorrhage (1.48%).

Conclusions: The global macroeconomic consequences related to stroke are vast even when considering stroke subtypes. The present quantification may be leveraged to help justify increased spending of finite resources on stroke in an effort to improve outcomes for patients with stroke globally.

Citing Articles

Dynamic Nomogram for Predicting the Fall Risk of Stroke Patients: An Observational Study.

Wu Y, Jiang X, Wang D, Xu L, Sun H, Xie B Clin Interv Aging. 2025; 20:197-212.

PMID: 40028259 PMC: 11871932. DOI: 10.2147/CIA.S486252.


Rurality and Outcomes of Patients Undergoing Mechanical Thrombectomy for Acute Ischemic Stroke.

Lavin C, Epstein J, Chen A, Cheema M, Yang J, Aquino A Crit Care Res Pract. 2025; 2025:4995600.

PMID: 39958465 PMC: 11824784. DOI: 10.1155/ccrp/4995600.


How many stroke survivors develop problematic spasticity requiring pharmacological therapy? An international (Europe and USA) observational study protocol.

Zorowitz R, Barrenechea L, Butet S, Groppa S, Hernandez Herrero D, Prasad R BMJ Open. 2025; 15(1):e087404.

PMID: 39819949 PMC: 11751951. DOI: 10.1136/bmjopen-2024-087404.


Projections of the Stroke Burden at the Global, Regional, and National Levels up to 2050 Based on the Global Burden of Disease Study 2021.

Cheng Y, Lin Y, Shi H, Cheng M, Zhang B, Liu X J Am Heart Assoc. 2024; 13(23):e036142.

PMID: 39575720 PMC: 11681572. DOI: 10.1161/JAHA.124.036142.


Mendelian randomization studies of lifestyle-related risk factors for stroke: a systematic review and meta-analysis.

Tian Y, Tang X, Liu Y, Liu S Front Endocrinol (Lausanne). 2024; 15:1379516.

PMID: 39558973 PMC: 11570884. DOI: 10.3389/fendo.2024.1379516.


References
1.
Byford S, Torgerson D, Raftery J . Economic note: cost of illness studies. BMJ. 2000; 320(7245):1335. PMC: 1127320. DOI: 10.1136/bmj.320.7245.1335. View

2.
Alkire B, Bergmark R, Chambers K, Lin D, Deschler D, Cheney M . Head and neck cancer in South Asia: Macroeconomic consequences and the role of the head and neck surgeon. Head Neck. 2016; 38(8):1242-7. DOI: 10.1002/hed.24430. View

3.
Corlew D, Alkire B, Poenaru D, Meara J, Shrime M . Economic valuation of the impact of a large surgical charity using the value of lost welfare approach. BMJ Glob Health. 2017; 1(4):e000059. PMC: 5321371. DOI: 10.1136/bmjgh-2016-000059. View

4.
Lu H, Tan Z, Liu Z, Wang L, Wang Y, Suo C . Spatiotemporal trends in stroke burden and mortality attributable to household air pollution from solid fuels in 204 countries and territories from 1990 to 2019. Sci Total Environ. 2021; 775:145839. DOI: 10.1016/j.scitotenv.2021.145839. View

5.
Bertram M, Sweeny K, Lauer J, Chisholm D, Sheehan P, Rasmussen B . Investing in non-communicable diseases: an estimation of the return on investment for prevention and treatment services. Lancet. 2018; 391(10134):2071-2078. DOI: 10.1016/S0140-6736(18)30665-2. View